Study identifier:D5050C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I, single-blind, randomised, placebo-controlled, single centre study to investigate the safety, tolerability and pharmacodynamics of intravenous MEDI8111 after single ascending doses in healthy male subjects
Healthy subjects
Phase 1
Yes
MEDI8111
Male
157
Interventional
18 Years - 40 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verified 01 Dec 2015 by AstraZeneca
AstraZeneca
-
A study to investigate the safety, tolerability and pharmacodynamics of MEDI8111 after single ascending doses in healthy male.
A phase I, single-blind, randomised, placebo-controlled, single centre study to investigate the safety, tolerability and pharmacodynamics of intravenous MEDI8111 after single ascending doses in healthy male subjects.
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: A MEDI8111 | Drug: MEDI8111 MEDI8111 lyophilisate for solution for infusion |
Placebo Comparator: B Placebo for MEDI8111 | Other: Placebo Placebo for MEDI8111 saline solution for infusion |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.